Core Laboratories N.V.
NYSE:CLBOil & Gas Equipment & Services
+$0.12 today
- Market cap
- $387.21M
- Beta
- 0.99
- P/E (TTM)
- 18.3
- EPS (TTM)
- $0.63
- Dividend yield
- 0.35%
Volume 0.52M
Average 0.49M
CLB Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Core Laboratories N.V.NYSE: CLB
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity rises 6.1% from a year ago
Total equity stood at $275.14M at the end of Q1 FY2026, up 6.1% from a year earlier and down 1.6% from the prior quarter. Over 3 fiscal years it compounded at +12.9% a year.
Context
- Total equity amounted to 46.8% of total assets at the end of Q1 FY2026, up 3.0 pp from a year earlier.
- Total equity increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps rising in the next quarterly balance sheet after a +6.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 272.21M USD
- Year-over-year change
- +5.6%
- 4-year CAGR
- +14.0%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 272.21M | +5.6% |
| FY2024 | 2024-12-31 | 257.74M | +12.2% |
| FY2023 | 2023-12-31 | 229.81M | +21.6% |
| FY2022 | 2022-12-31 | 188.95M | +17.4% |
| FY2021 | 2021-12-31 | 161M | — |
Total Equity vs competitors
How CLB compares with its peers on the latest reported figures
- Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +6.1% is the 3rd highest of 10, against a peer median of -4.3%.
- Total equity amounts to 46.8% of total assets for CLB, versus a peer median of 44.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | CA$1.63B CAD | -4.3% | +8.9% | 59.1% | |
| Mar 2026 | $1.47B USD | -10.1% | +10.9% | 44.7% | |
| Mar 2026 | $1.44B USD | -0.3% | +5.8% | 32.9% | |
| Mar 2026 | $1.2B USD | +22.8% | +10.8% | 31.5% | |
| Mar 2026 | $604.47M USD | +2.7% | +9.9% | 45.7% | |
| Mar 2026 | $570.45M USD | -14.6% | +3.4% | 64.6% | |
| Mar 2026 | $545.64M USD | -13.6% | -3.0% | 45.7% | |
| Mar 2026 | $421.86M USD | +50.3% | +25.2% | 24.4% | |
| Mar 2026 | $275.14M USD | +6.1% | +12.9% | 46.8% | |
| Mar 2026 | -$78.45M USD | -39.3% | — | 7.8% | |
| Peer median (excluding CLB) | — | -4.3% | +9.4% | 44.7% | |
Competitors are the stored peer set for CLB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 17.7M | 15.43M | 15.12M | 19.16M | 22.7M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 106.74M | 115.1M | 123.07M | 127.36M | 120.8M |
| Inventory | 45.44M | 60.45M | 71.7M | 59.4M | 54.5M |
| Other Current Assets | 5.11M | 5.06M | 5.09M | 10.52M | 6.94M |
| Total Current Assets | 189.06M | 211.7M | 223.14M | 226.61M | 214.67M |
| Property, Plant & Equipment (Net) | 172.34M | 157.41M | 153.47M | 153.55M | 153.79M |
| Goodwill | 99.45M | 99.45M | 99.45M | 99.45M | 105.79M |
| Intangible Assets | 8.14M | 7.48M | 6.93M | 6.4M | 7.12M |
| Long-term Investments | 4.16M | 4.45M | 4.84M | 5.08M | 4.43M |
| Tax Assets | 70.46M | 68.57M | 69.2M | 69.61M | 67.38M |
| Other Non-current Assets | 37.26M | 29.3M | 98.58M | 29.71M | 30.84M |
| Total Non-current Assets | 391.8M | 366.65M | 363.26M | 363.8M | 369.35M |
| Total Assets | 580.85M | 578.35M | 586.4M | 590.41M | 584.01M |
| Account Payables | 29.73M | 45.85M | 33.51M | 34.55M | 37.28M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 12.43M | 7.86M | 7.28M | 11.96M | 0 |
| Deferred Revenue | 7.77M | 5.94M | 4.76M | 9.33M | 5.55M |
| Other Current Liabilities | 13.61M | 13.18M | 13.59M | 8.16M | 20.95M |
| Total Current Liabilities | 90.78M | 103.14M | 88.1M | 97.59M | 106.02M |
| Long-term Debt | 188.64M | 172.39M | 163.13M | 126.11M | 110.26M |
| Deferred Tax Liabilities | 24.34M | 22.88M | 12.7M | 13.78M | 8M |
| Deferred Revenue (Non-current) | 39.1M | 31.81M | 30.54M | 0 | 29.38M |
| Other Non-current Liabilities | 27.71M | 20.88M | 20.04M | 51.85M | 15.85M |
| Total Non-current Liabilities | 329.07M | 286.27M | 268.49M | 235.08M | 205.79M |
| Total Liabilities | 419.85M | 389.4M | 356.59M | 332.67M | 311.8M |
| Common Stock | 1.19M | 1.19M | 469K | 470K | 470K |
| Retained Earnings | 68.35M | 85.95M | 120.76M | 150.28M | 172.66M |
| Accumulated OCI | (10.13M) | (3.78M) | (4.97M) | (5.77M) | (5.81M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 4.55M | 4.7M | 4.99M | 5.75M | 6.22M |
| Total Equity | 161M | 188.95M | 229.81M | 257.74M | 272.21M |
| Total Debt | 250.26M | 222.39M | 215.39M | 180.14M | 164.02M |
| Net Debt | 232.56M | 206.96M | 200.27M | 160.99M | 141.32M |
Core Laboratories N.V.
NYSE:CLB
Intrinsic Alpha fair value
Locked
Current Price
$8.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.